Short answer
UTAH MEDICAL PRODUCTS INC (UTMD) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 99.1 (), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 covers UTMD results for the three and nine months ended September 30, 2026.
UTAH MEDICAL PRODUCTS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 covers UTMD results for the three and nine months ended September 30, 2026
- Press release dated October 22, 2026 includes forward-looking statements for 2026 and beyond
- Investor focus: quarterly operating performance and management’s outlook, detailed in Exhibit 99.1
Item 99.1 ·
- Press release covers fiscal 2026 and nine months ended September 30, 2026
- Forward-looking statements address 2026 and beyond, relevant to expectations but subject to execution risks
- CEO Kevin L. Cornwell signed the filing on October 22, 2026
Item EX-99.1 · Exhibit EX-99.1
- 3Q revenue $8.621M, down 12.1%, reflecting lost PendoTECH and China distributor sales plus weaker Filshie demand
- 3Q net income $2.787M, up 5.9%, and diluted EPS $0.876, up 6.8%, supported by lower litigation, amortization and taxes
- 9M revenue $25.873M, down 12.2%, while net income fell 7.4% to $8.077M and EPS declined 5.3% to $2.537
- Orion acquisition added $619K of 3Q sales for $5.0M, but biopharma replacement sales remain slower than expected
- Debt-free balance sheet with $85.2M cash and investments, alongside $3.0M dividends and $0.9M share repurchases year to date
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UTAH MEDICAL PRODUCTS INC 8-K filings
Get the next UTMD 8-K as it lands
Follow UTMD for push alerts, or ask the research agent what this filing means.